Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 04 2020
Historique:
received: 29 05 2019
revised: 21 11 2019
accepted: 28 01 2020
pubmed: 8 2 2020
medline: 21 10 2020
entrez: 8 2 2020
Statut: ppublish

Résumé

For maximal oncogenic activity, cellular MYC protein levels need to be tightly controlled so that they do not induce apoptosis. Here, we show how ubiquitin ligase UBR5 functions as a molecular rheostat to prevent excess accumulation of MYC protein. UBR5 ubiquitinates MYC and its effects on MYC protein stability are independent of FBXW7. Silencing of endogenous UBR5 induced MYC protein expression and regulated MYC target genes. Consistent with the tumor suppressor function of UBR5 (HYD) in Drosophila, HYD suppressed dMYC-dependent overgrowth of wing imaginal discs. In contrast, in cancer cells, UBR5 suppressed MYC-dependent priming to therapy-induced apoptosis. Of direct cancer relevance,

Identifiants

pubmed: 32029551
pii: 0008-5472.CAN-19-1647
doi: 10.1158/0008-5472.CAN-19-1647
doi:

Substances chimiques

DNA-Binding Proteins 0
Drosophila Proteins 0
MYC protein, human 0
Myc protein, Drosophila 0
Proto-Oncogene Proteins c-myc 0
Transcription Factors 0
UBR5 protein, human EC 2.3.2.26
hyd protein, Drosophila EC 2.3.2.26
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1414-1427

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Xi Qiao (X)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Institute of Biomedicine, University of Turku, Turku, Finland.
TuDMM Doctoral Programme, University of Turku, Turku, Finland.

Ying Liu (Y)

Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.
Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

Maria Llamazares Prada (ML)

Theodor Boveri Institute and Comprehensive Cancer Center, Mainfranken, Biocenter, University of Würzburg, Würzburg, Germany.

Aravind K Mohan (AK)

Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.

Abhishekh Gupta (A)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

Alok Jaiswal (A)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

Mukund Sharma (M)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Institute of Biomedicine, University of Turku, Turku, Finland.
TuDMM Doctoral Programme, University of Turku, Turku, Finland.

Joni Merisaari (J)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Institute of Biomedicine, University of Turku, Turku, Finland.
TuDMM Doctoral Programme, University of Turku, Turku, Finland.

Heidi M Haikala (HM)

Research Programs Unit/Translational Cancer Medicine & HiLIFE, University of Helsinki, Helsinki, Finland.

Kati Talvinen (K)

Institute of Biomedicine, University of Turku, Turku, Finland.

Laxman Yetukuri (L)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.

Joanna W Pylvänäinen (JW)

Turku BioImaging, University of Turku and Åbo Akademi University, Turku, Finland.

Juha Klefström (J)

Research Programs Unit/Translational Cancer Medicine & HiLIFE, University of Helsinki, Helsinki, Finland.

Pauliina Kronqvist (P)

Institute of Biomedicine, University of Turku, Turku, Finland.

Annika Meinander (A)

Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland.

Tero Aittokallio (T)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Department of Mathematics and Statistics, University of Turku, Turku, Finland.

Ville Hietakangas (V)

Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.
Institute of Biotechnology, University of Helsinki, Helsinki, Finland.

Martin Eilers (M)

Theodor Boveri Institute and Comprehensive Cancer Center, Mainfranken, Biocenter, University of Würzburg, Würzburg, Germany.

Jukka Westermarck (J)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. jukka.westermarck@bioscience.fi.
Institute of Biomedicine, University of Turku, Turku, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH